Clinical Trial Update: Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

View source ↗

Summary

Expanded Access program offering neoantigen synthetic long peptide vaccines to patients with local or metastatic solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Neoantigen Synthetic Long Peptide Vaccine

Snippet

Sponsor: Jaime Leandro Foundation for Therapeutic Cancer Vaccines | Conditions: Cancer | Status: AVAILABLE